Mangoceuticals Rockets 33.8% on $2.3M Equity Raise, Launches PeachesRx & Smokeless Pouches

Introduction

Mangoceuticals Inc (NASDAQ: MGRX) is a Dallas-based telemedicine company specializing in men’s wellness products and services. Through an online platform, the firm connects customers with licensed healthcare professionals and fulfills prescriptions via a licensed pharmacy network. Its product portfolio includes treatments for erectile dysfunction, testosterone replacement therapy, and other men’s health concerns.

Corporate Structure

Founded with a team of fewer than ten employees, Mangoceuticals operates as a public company under CIK 0001938046. Chief Executive Officer Jacob Cohen leads the management team, supported by telehealth providers and fulfillment partners. The company’s headquarters in Dallas, Texas, serves as its operations and logistics hub.

Telemedicine by Mary Eineman

Developments and News

In March 2025, CEO Jacob Cohen presented at the 8th Annual Growth Conference, discussing the firm’s approach to men’s health solutions. A strategic expansion into the smokeless pouch market was announced in mid-2025 with the acquisition of Smokeless Technology IP, aimed at diversifying delivery methods. In September 2025, the company launched PeachesRx, a women’s telehealth brand, which was highlighted at a Nasdaq event. Additionally, as of November 1, 2025, MangoRx services became available in California, expanding its geographic reach.

A securities offering on December 19, 2025, under a Form 424B5 prospectus included the issuance of 1,430,502 shares of common stock at $1.295 per share and 500,000 pre-funded warrants exercisable at $0.00001, resulting in approximately $2.32 million in net proceeds. Concurrently, private placement warrants for 1,930,502 shares at $1.4245 were sold. Placement agent fees totaled 7% of the aggregate purchase price, amounting to about $175,000.

Financial and Strategic Analysis

As of December 22, 2025, MGRX closed at $0.9542, a 33.83% increase from the prior trading day, with a volume of 1,744,168 shares. The stock’s market capitalization is approximately $10 million. Key metrics for the trailing twelve months include a price/sales ratio of 10.96, a price/book ratio of 0.63, revenue of $466,910, and a net loss of $20.77 million. The balance sheet shows $481,280 in cash and a debt-to-equity ratio of 0.71%. Levered free cash flow totaled $689,680.

The equity raised in December is intended to support product development, enhancements to the telemedicine platform, and market expansion. The issuance of pre-funded and private warrants offers capital-raising flexibility while aiming to limit immediate dilution.

Market Position and Industry Context

Mangoceuticals competes in the digital health and direct-to-consumer wellness sector, where telemedicine adoption has grown in response to consumer demand for convenience and privacy. The company exhibits high volatility, with a five-year beta of 2.57. Key challenges include navigating regulatory approval processes, adapting to evolving reimbursement models, and managing competition from established telehealth providers. Given its small market cap and limited revenue base, the company’s future growth will be influenced by its capacity to execute expansion initiatives and efficiently utilize capital from the December 2025 offering.

tl;dr

Mangoceuticals’ stock rose 33.83% to $0.9542 on December 22, 2025, following a December 19 equity and warrant offering that raised about $2.32 million. The company has acquired Smokeless Technology IP for pouch delivery, launched PeachesRx for women’s telehealth, and expanded MangoRx services into California, positioning itself for growth in telemedicine in 2026.